Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) (Q58023972)
Jump to navigation
Jump to search
article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) |
article |
Statements
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) (English)
Heike Pfeifer
Barbara Wassmann
Anna Pavlova
Lydia Wunderle
Johannes Oldenburg
Anja Binckebanck
Thoralf Lange
Silvia Wystub
Patrick Brück
Dieter Hoelzer
3 April 2007